FLJ41047 Inhibitors
FLJ41047 inhibitors encompass a diverse array of chemical compounds that act on different cellular signaling pathways and biological processes, ultimately leading to the inhibition of FLJ41047 activity. Staurosporine, by inhibiting protein kinase C, can prevent the phosphorylation and subsequent activation of FLJ41047, assuming that this protein is phosphorylated by PKC for its function. LY294002 and Wortmannin, both PI3K inhibitors, suppress the PI3K/AKT pathway, which could result in a decrease in FLJ41047 activity if it is an AKT substrate. Similarly, the mTOR inhibitor Rapamycin can impede the mTORC1 signaling, potentially inhibiting FLJ41047 if its expression or activity is mTOR-dependent.
Further, the MAPK signaling pathway inhibitors, SB203580 and PD98059, as well as the JNK inhibitor SP600125, can decrease FLJ41047 activity by disrupting the upstream kinase signaling required for its activation. U0126, another MEK inhibitor, might inhibit FLJ41047 by the same mechanism if it relies on ERK-mediated phosphorylation. Leflunomide's inhibition of pyrimidine synthesis could reduce the levels of FLJ41047 if it needs pyrimidine-rich sequences for stability or function. Brefeldin A's disruption of protein trafficking can prevent proper processing of FLJ41047 if it is necessary for its functionality. Cyclosporin A, through the inhibition of calcineurin,could reduce FLJ41047 activity if the protein is regulated by dephosphorylation. Lastly, 2-Deoxy-D-glucose can indirectly inhibit FLJ41047 by depleting cellular ATP levels required for its activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
A potent protein kinase C inhibitor that can suppress multiple kinase-dependent signaling pathways. Inhibition of protein kinase C can downregulate FLJ41047 if it relies on phosphorylation by this kinase for its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A phosphoinositide 3-kinases (PI3K) inhibitor that impedes the PI3K/AKT pathway. FLJ41047, if functioning downstream of AKT, would be inactivated due to reduced AKT-mediated phosphorylation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that, by inhibiting downstream signaling of mTORC1, can lead to reduced protein synthesis and hinder proteins like FLJ41047 if they are regulated by mTOR-dependent mechanisms. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
A steroidal metabolite that acts as an irreversible inhibitor of PI3K. By blocking the PI3K/AKT pathway, it would prevent any potential activation of FLJ41047 by AKT. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor that would impede the MAPK signaling cascade. If FLJ41047 functions downstream of p38 MAPK, its activity would be diminished due to lack of MAPK-mediated activation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK) that would disrupt the JNK signaling pathway. If FLJ41047 is activated by JNK phosphorylation, this compound would lead to its inactivation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A MEK inhibitor that blocks the MAPK/ERK pathway. If FLJ41047 is regulated via ERK-mediated phosphorylation, its activity would be inhibited by PD98059. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
Another MEK inhibitor, similar to PD98059, that specifically inhibits MEK1 and MEK2, leading to downstream reduction in ERK activity and potentially inhibiting FLJ41047 if it is ERK-dependent. | ||||||
Leflunomide | 75706-12-6 | sc-202209 sc-202209A | 10 mg 50 mg | $20.00 $81.00 | 5 | |
A dihydroorotate dehydrogenase inhibitor that can lead to diminished pyrimidine synthesis. This reduction can indirectly inhibit FLJ41047 if it requires pyrimidine-rich sequences for its function. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
An inhibitor of ADP-ribosylation factor (ARF), which disrupts protein trafficking from the ER to the Golgi apparatus. This could inhibit FLJ41047 if it requires Golgi processing for its function. | ||||||